MedTrace Logo

Limiting Chemotherapy Side Effects by Using Moxa

NCT02781155 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2016-05-24

No results posted yet for this study

Summary

This study investigates whether it is feasible to teach cancer patients undergoing chemotherapy to self-administer daily moxibustion to reduce chemotherapy side effects. Moxibustion is a therapy used in traditional Chinese medicine that uses heat.

Conditions

  • Breast Neoplasms
  • Colorectal Neoplasms
  • Genital Neoplasms, Female
  • Toxicity Due to Chemotherapy

Interventions

OTHER

Moxibustion

Participants are taught to self administer moxibustion to acupuncture point Zusanli St-36 daily throughout the course of their chemotherapy

Sponsors & Collaborators

  • British Acupuncture Council

    collaborator OTHER

  • East and North Hertfordshire NHS Trust

    lead OTHER_GOV

Principal Investigators

  • Beverley A de Valois, PhD · Lynda Jackson Macmillan Centre, Mount Vernon Cancer Centre

Study Design

Allocation
NA
Purpose
SUPPORTIVE_CARE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-02-29
Primary Completion
2017-01-31
Completion
2017-09-30

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02781155 on ClinicalTrials.gov